GlassScriptPhysician profile
Trevor Brown
NPI 1558115691
$4,111.87
in general payments reported to CMS, 2019-2025
20 companies · $3,198 in 2025
The $3,198 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $914 · 2025: $3,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,012 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,011.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $934.73 | 2024-2025 | Krystexxa, Otezla, Evenity |
| Abbvie INC. | $769.95 | 2024-2025 | |
| Ucb, INC. | $401.25 | 2024-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $319.29 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $250.63 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $218.03 | 2024-2025 | Acthar |
| Radius Health, INC. | $173.32 | 2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $172.04 | 2024-2025 | Saphnelo |
| Genzyme Corporation | $153.35 | 2025 | |
| Lilly USA, LLC | $114.67 | 2024-2025 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $102.73 | 2024-2025 | Orencia |
| Pfizer INC. | $87.44 | 2024-2025 | |
| Genentech USA, INC. | $76.57 | 2024-2025 | Actemra, Gazyva |
| Ani Pharmaceuticals, INC. | $64.30 | 2024-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $64.26 | 2024-2025 | Lupkynis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $60.09 | 2025 | Opsumit |
| Fresenius Kabi USA, LLC | $58.32 | 2025 | Tyenne |
| Glaxosmithkline, LLC. | $45.60 | 2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $22.70 | 2025 | Strensiq |
| Tersera Therapeutics LLC | $22.60 | 2025 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.